Health systems are continuously being challenged to ensure IV preparations are prepared safely and accurately while complying with increasingly complex regulations. As a result, many rely on 503B outsourcing pharmacies to provide the vast majority of their pre-mixed compounded sterile products. But as product shortages and pricing fluctuations in the supply chain become more acute, rather than provide relief, 503Bs actually can put more pressure on pharmacy staffs and budget.
Joining host Ken Perez to discuss are pharmacy leaders who met those challenges by going against the trend – by insourcing their sterile compounding, with a twist.
Joseph J. DiCubellis, RPh, MPH, Senior Director of Pharmacy Services for the University of Maryland Medical System and Senior Director of Pharmacy, University of Maryland Medical Center
Yevgeniya Kogan-Hardesty, PharmD, BCSCP, Sterile Compounding, Pharmacy Manager, University of Maryland Medical Center
Podden och tillhörande omslagsbild på den här sidan tillhör
Omnicell. Innehållet i podden är skapat av Omnicell och inte av,
eller tillsammans med, Poddtoppen.
